Inne Borel

Pancreatic neuroendocrine neoplasms (pNEN) comprise less than 5% of all pancreatic neoplasms. Despite their rarity, the incidence has steadily increased in both the USA and Europe over recent decades1,2. In Europe, their age-standardized incidence reached 1 per 100 000 inhabitants in 2018 and an average annual increase of 110.6% was observed2.

Abstract Background In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of CMS4 is hampered by locoregional and temporal variables influencing CMS classification. Diagnostic tools that comprehensively detect CMS4 are therefore urgently needed. Methods To identify targets for molecular CMS4 imaging, RNA sequencing data of 3232 primary CRC patients were explored.